MSL
RVNC

Mackay Shields LLC’s Revance Therapeutics, Inc. RVNC Stock Holding History

Mackay Shields LLC’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,500
Closed -$213K – 1570
2020
Q4 		$213K Buy
+7,500
New +$194K ﹤0.01% 1408

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Mackay Shields LLC's RVNC Position: Q1 2021 in Review

Mackay Shields LLC sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2021, closing a stake of 7,500 shares — an estimated $213K sold.

Mackay Shields LLC first reported a position in RVNC in Q4 2020 and held it in 1 quarter. The position peaked at $213K in Q4 2020. 149 funds tracked by Wall St. Rank hold RVNC as of Q1 2021.

  • Mackay Shields LLC reported no remaining Revance Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 7,500 Revance Therapeutics, Inc. shares in Q1 2021, an estimated $213K.
  • Mackay Shields LLC first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 1 quarter.
  • Mackay Shields LLC's Revance Therapeutics, Inc. position peaked at $213K in Q4 2020.
  • 149 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2021.

Based on Mackay Shields LLC's 13F filing for Q1 2021, filed 14 May 2021.